Back to Blog
Venture forthe inc ny5/5/2023 ![]() ![]() Picked by: Weiss Pick and Schlidt, investor Total raised: Undisclosed amount of seed funding from 10X Capital in May 2021, according to Crunchbase. 3, 2007, file photo magic mushrooms are seen in a grow room at the Procare farm in Hazerswoude, central Netherlands. Langer said the team's scientific expertise, focus on good relationships with stakeholders, and their deep understanding of plant medicines have impressed him and his firm.įILE - in this Aug. "The company is extremely capital efficient due to streamlined Swiss regulations and an experienced clinical-science team integrated with the University of Zurich," he added. Why investors like the company: Belotsky said he believes that the company's "precision approach" to pharmacology and therapeutics will create compounds that work better and are safer than current medicines. Its lead compound is based on DMT, a potent psychoactive chemical that's originally found in a plant and is a key ingredient in the psychedelic brew ayahuasca. What the company does: Reconnect Labs is developing psychedelic treatments for psychiatric and neurodegenerative disorders. Picked by: Ken Belotsky, a partner at Negev Capital, investor and Langer, investor Langer said that Osmind is the only psychedelics startup to have a pre-seed round where Lionheart Ventures wanted to invest, "but the round moved too fast for us and we missed out." Serebrinsky said that the data that Osmind collects could help treatments qualify for insurance coverage and may pave the way for safer and more effective treatments than ketamine, which can be addictive. "They have managed to bring reputable VC funds such as General Catalyst on board, which has lent additional validation and credibility to their platform," Schlidt said. Why investors like the company: Schlidt said that the company is a pioneer creating an electronic health record for ketamine clinics and has "rockstar founders." What the company does: Osmind is a software platform that allows mental-health providers to administer psychedelics therapy, monitor patient outcomes, streamline workflows, and prescribe drugs. Picked by: Tim Schlidt, a cofounder and partner at Palo Santo Serebrinsky and David Langer, a founding partner at Lionheart Ventures Jimmy Qian, a cofounder and the president of Osmind and Lucia Huang, a cofounder and the CEO of Osmind. Muslimov said that his fund invested in Beckley in part because of their seasoned team and the high therapeutic potential of 5-MeoDMT, the psychoactive compound found in the Sonoran Desert toad and some plants. Why investors like the company: In addition to Beckley's roots with the foundation, Chomer said that Beckley has also recently strengthened its pipeline and development team with the acquisition of the psychedelics company Eleusis Therapeutics. ![]() The company is developing treatments for treatment-resistant depression, alcohol-abuse disorder, and major-depressive disorder. It got its start when the Beckley Foundation, a nonprofit focused on drug-policy reform and research into psychoactive substances, began to look for business opportunities to pursue drug development. What the company does: Beckley Psytech is developing psychedelics-based treatments for neuropsychiatric disorders. Picked by: Andrew Chomer, managing partner at Integrated, investor and Bek Muslimov, a cofounding partner at Leafy Tunnel, investor Total raised: £84 million, or about $103.5 million ![]() It often indicates a user profile.Ĭosmo Feilding Mellen, a cofounder and the CEO of Beckley Psytech, and Amanda Feilding, a cofounder of Beckley Psytech. Account icon An icon in the shape of a person's head and shoulders. ![]()
0 Comments
Read More
Leave a Reply. |